

SYNLAB and OWL Metabolomics enter into a Strategic Alliance for the Commercialization in Spain of the OWLiver® Test, the unique non-invasive diagnostic for NAFLD/NASH.

MADRID and DERIO, SPAIN, October 31st 2018

SYNLAB, a leading company in medical diagnostic services in the European Market and **OWL Metabolomics**, a biotechnology company in the field of Metabolomics with pioneering diagnostics products, announce its strategic alliance for the commercialization of the **OWLiver®** test, the unique robust and non-invasive blood-based test for the diagnosis of non-alcoholic fatty liver (NAFL) and non-alcoholic steato-hepatitis (NASH) based in the lipidomic analysis.

This initiative aims to facilitate the access of the NASH non-invasive diagnostic test (**OWLiver®**) to the Spanish private hospitals and healthcare institutions. At present **OWL Metabolomics** has introduced this test in a broad network of public hospitals where the test **OWLiver®** can be already prescribed by physicians. With the present agreement, the availability of the **OWLiver®** test will be extended practically to the complete healthcare systems in the territory through the SYNLAB laboratory network.

About NAFLD/NASH

Non-alcoholic fatty liver disease (NAFLD), comprising from steatosis to non-alcoholic steato-hepatitis (NASH), in its worse progress of the disease, can lead to extensive scarring (cirrhosis) and associated complications and liver cancer. NAFLD, highly correlated to obesity and diabetes, is currently affecting 20-30% of the general population and it's foreseen to be the main cause of liver transplantation in the coming years.

About OWL Metabolomics

OWL Metabolomics is a biotechnology company committed to the identification, validation and global commercialization of novel diagnostic assays for the liver and other highly prevalent human diseases, including the identification of potential therapeutic targets involved in the development of such diseases. OWL has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in new drug development.

The **OWLiver®** assay is the world's first metabolomics-based in-vitro test for diagnosing non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

For more information on OWL technology, visit
<http://www.owlmetabolomics.com/liver-disease-diagnosis.aspx>

About SYNLAB

The SYNLAB group is Europe's number one medical diagnostics service provider, offering the full range of medical laboratory services for patients, practicing doctors, clinics and the pharmaceutical industry

The Company is present in more than 40 countries in 4 continents keeping a leadership position in the majority of its markets. More than 20.000 employees contribute every day to the group's success. SYNLAB manages over 500 million of laboratory tests per year generating revenues for more than 1,700 million of Euros.

For more information on tests and services visit: www.synlab.es

OWL Metabolomics (One Way Liver, S.L.)
Technology Park of Bizkaia
Building 502- 48160 Derio - Bizkaia - Spain
www.owlmetabolomics.com

Synlab Diagnósticos Globales, SA
C/ Verge De Guadalupe, 18
08950 Esplugues De Llobregat - Barcelona - Spain
www.synlab.es